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Effect of polymorphisms in folate-related genes on in vitro methotrexate
sensitivity in pediatric acute lymphoblastic leukemia
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Frits G. J. Peters, Yaddanapudi Ravindranath, Rob Pieters, and Jan Lindemans
We studied whether common polymor-
phisms in genes involved in folate metabo-
lism affect methotrexate (MTX) sensitivity.
Ex vivo MTX sensitivity of lymphoblasts
obtained from pediatric patients with acute
lymphoblastic leukemia (ALL; n 157) was
determined by the in situ thymidylate syn-
thase inhibition assay after either continu-
ous (21 hours; TSI50, cont) or short-term (3
hours; TSI50, short) MTX exposure. DNA was
isolated from lymphoblasts obtained from
cytospin slides. Polymorphisms in methyl-
enetetrahydrofolate reductase (MTHFR
677C>T, MTHFR 1298A>C), methionine
synthase (MTR 2756A>G), methionine
synthase reductase (MTRR 66A>G),
methylenetetrahydrofolate dehydroge-
nase (MTHFD1 1958G>A), serine hydroxy-
methyl transferase (SHMT1 1420C>T),
thymidylate synthase (TS 2R3R), and the
reduced folate carrier (RFC 80G>A) were
detected by polymerase chain reaction–
restriction fragment length polymorphism
(PCR-RFLP) or real-time PCR. Patients
with the MTHFR 1298AC variant or the
MTRR 66 G-allele showed decreased in
vitro MTX sensitivity measured under both
test conditions. SHMT1 1420TT homozy-
gotes only showed decreased MTX sensi-
tivity in the TSI50, cont. In conclusion, poly-
morphisms in the folate-related genes
MTHFR, MTRR, and SHMT1 are related to
MTX resistance in pediatric patients with
ALL. (Blood. 2005;106:717-720)
© 2005 by The American Society of Hematology
Introduction
Reduced tetrahydrofolates (THFs) serve as cofactors that carry
one-carbon moieties for (1) the synthesis of de novo purines and
thymidylate (dTMP) and (2) remethylation of homocysteine to
methionine (Figure 1). The antifolate methotrexate (MTX) and its
active polyglutamate forms inhibit RNA and DNA synthesis in
cells by inhibiting dihydrofolate reductase (DHFR) and thymidy-
late synthase (TS), respectively, 2 crucial enzymes in pyrimidine
synthesis and folate recirculation (Figure 1). MTX is an important
chemotherapeutic drug in the treatment of acute lymphoblastic
leukemia (ALL) and other malignancies. Recent clinical and in
vitro studies indicate that common polymorphisms in genes coding
for enzymes involved in folate metabolism affect the sensitivity of
patients to folate-based chemotherapeutic drugs such as MTX.1-10
This may be a direct effect or indirect due to shifts in intracellular
folate distribution.9,11 We investigated whether common polymor-
phisms in folate-related genes influence (ex vivo) MTX sensitivity.
Study design
From newly diagnosed Western European pediatric patients with ALL,
peripheral blood or bone marrow mononuclear cells were isolated with
Ficoll Isopaque ( 80% leukemic cell enrichment) and MTX sensitivity
was previously measured with the in situ thymidylate synthase inhibition
assay (TSI).12,13 In short, leukemia cells were incubated with different
concentrations of MTX for 21 hours (TSIcont) or for 3 hours followed by an
18-hour drug-free period (TSIshort), after which the degree of inhibition of
TS was measured using [5-3H]-2-deoxycytidine as substrate.12 TSI data
were expressed as the concentration of MTX needed to inhibit 50% of the
control TS activity (TSI50). Due to limited cell numbers, of all 157 patients
included in this study, the TSI50, cont was measured in 86 patients and the
TSI50, short in 120 patients. DNA was obtained from unstained cytospin slides
of 157 patients. Informed consent from each patient was obtained according
to local procedures in accordance with the Declaration of Helsinki.
Genomic DNA was isolated using the QIAmp DNA Mini Blood Kit
(Qiagen, Vealo, Netherlands). PCR-RFLP was used to detect polymor-
phisms in methylenetetrahydrofolate reductase (MTHFR 677CT, MTHFR
1298AC),14,15 methionine synthase (MTR 2756AG),16 serine hydroxy-
methyl transferase (SHMT1 1420CT),17 methylenetetrahydrofolate dehy-
drogenase (MTHFD1 1958GA),18 and the reduced folate carrier (RFC
80GA).19 Double (2R2R) or triple (3R3R) 28-bp tandem repeats in the
promoter region of the thymidylate synthase gene (TS 2R3R) were
visualized on agarose gel directly after the PCR reaction.20 The polymor-
phism in the methionine synthase reductase gene (MTRR 66AG) was
determined with real-time PCR using hybridization probes and Lightcycler
Technology (Roche, Mannheim, Germany). Because TSI data were not
normally distributed, ln (natural logarithm)–transformed TSI values were
used as outcome measure in univariate and multivariate regression analysis.
Results and discussion
For each genetic variant, the median (50th percentile) and interquar-
tile range (25th-75th percentile) for the TSI50, cont and the TSI50, short
is presented in Tables 1 and 2. Univariate regression analysis
revealed MTHFR 1298AC (P  .01), MTRR 66AG (P  .08), and
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MTRR 66GG (P  .09) as potential determinants of TSI50, cont;
MTHFR 1298AC (P  .03), MTRR 66AG (P  .001), and MTRR
66GG (P  .02) were determinants of TSI50, short. Multiple regres-
sion analysis identified MTHFR 1298AC (P  .06), MTRR 66AG
(P  .08), and SHMT1 1420TT (P  .04) as determinants of TSI50,
cont; determinants of TSI50, short were MTHFR 1298AC (P  .01),
MTRR 66AG (P  .001), and MTRR 66GG (P  .03).
This is the first report describing the influence on a large
population of several genetic polymorphisms in folate-related
genes on ex vivo MTX sensitivity. Our results show that patients
with the MTRR 66 G-allele and the MTHFR 1298AC variant are
less sensitive to MTX in both the TSI50, cont and the TSI50, short.
Interestingly, both polymorphisms were also related to hematologic
toxicity (manuscript in preparation). The MTHFR 677CT poly-
morphism was not related to sensitivity in this study. In fact,
published data on the role of MTHFR 677CT are quite contradic-
tory. Patients carrying the MTHFR 677CT polymorphism are at a
higher risk of developing MTX-related toxicity,2,4,8 whereas in an
earlier small pilot study (n  6), greater MTX sensitivity was
observed in the 2 MTHFR 677TT patients.6 The MTHFR
677T1298A haplotype or the MTHFD1 1958A variant, in interac-
tion with the TS 3R repeat, resulted in a decreased event- and
Figure 1. Simplified scheme depicting intracellular metabolism of folates. For
clarity reasons, the reaction catalysed by methylenetetrahydrofolate dehydrogenase/
methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthetase (MTHFD1)
is not shown; MTHFD1 converts CH2-THF in 3 steps to THF and provides formyl-THF
(CHO-THF) for purine synthesis. THF indicates tetrahydrofolate; DHF, dihydrofolate;
CH2-THF, methylene-THF; CH3-THF, methyl-THF; SAM, S-adenosylmethionine;
SAH, S-adenosylhomocysteine; dTMP, deoxy thymidine monophosphate; dUMP,
deoxy uridine monophosphate; TS, thymidylate synthase; MTHFR, methylenetetrahy-
drofolate reductase; MS, methionine synthase; MTRR, methionine synthase reduc-
tase; SHMT, serine-hydroxymethyltransferase; DHFR, dihydrofolate reductase; RFC,
reduced folate carrier; MTX-PG, methotrexate-polyglutamate; and NADP, nicotin-
amide adenine dinucleotide.
Table 1. Univariate analysis of the effect of polymorphisms in folate-related genes on in vitro MTX sensitivity (TSI50) of childhood ALL
Polymorphism
Univariate analysis
TSI50,cont, M TSI50,short, M
n Median [IQR] n Median [IQR]
MTHFR 677C > T
CC 47 0.071 [0.041-0.195] 68 0.562 [0.156-4.978]
CT 31 0.063 [0.038-0.155] 39 0.540 [0.156-3.500]
TT 8 0.090 [0.037-0.168] 13 1.481 [1.037-3.250]
MTHFR 1298A > C
AA 36 0.052 [0.030-0.124] 51 0.600 [0.156-1.488]
AC 36 0.107 [0.055-0.225]† 49 0.904 [0.156-8.656]‡
CC 14 0.082 [0.034-0.194] 20 0.479 [0.156-3.449]
MTR 2756 A > G
AA 54 0.103 [0.035-0.180] 77 0.600 [0.156-6.059]
AG 26 0.052 [0.038-0.117] 36 0.661 [0.156-1.795]
GG 6 0.098 [0.056-0.204] 7 0.906 [0.156-1.460]
MTRR 66A > G
AA 23 0.054 [0.038-0.088] 29 0.156 [0.156-0.560]
AG 37 0.104 [0.038-0.191]§ 54 1.260 [0.169-7.658]
GG 26 0.112 [0.038-0.190]¶ 36 0.984 [0.156-4.802]‡
MTHFD1 1958G > A
GG 26 0.120 [0.033-0.196] 35 0.830 [0.156-2.840]
GA 48 0.065 [0.041-0.164] 67 0.762 [0.156-5.310]
AA 12 0.053 [0.036-0.174] 18 0.560 [0.156-2.653]
SHMT1 1420 C > T
CC 49 0.063 [0.037-0.161] 74 0.661 [0.156-4.096]
CT 30 0.067 [0.037-0.182] 35 0.600 [0.156-3.500]
TT 7 0.133 [0.088-0.235] 11 1.131 [0.410-5.614]
TS 2R3R
3R3R 25 0.059 [0.039-0.192] 42 0.951 [0.156-5.255]
3R2R 42 0.069 [0.035-0.132] 52 0.398 [0.156-2.963]
2R2R 19 0.151 [0.050-0.181] 25 1.042 [0.178-5.384]
RFC 80G > A
GG 30 0.058 [0.034-0.173] 43 0.580 [0.156-1.858]
GA 43 0.071 [0.036-0.188] 54 0.508 [0.156-3.620]
AA 12 0.080 [0.044-0.163] 20 1.110 [0.190-9.315]
IQR indicates interquartile range.
†P .01.
‡P .05.
§P .08.
P .001.
¶P .09.
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disease-free survival in pediatric patients with ALL treated with
MTX.10 Sohn et al9 transfected human colon and breast cancer cells
with either wild-type or mutant 677T human MTHFR cDNA. Only
mutant cells had decreased MTHFR activity, changed intracellular
folate distribution, increased TS activity, and decreased chemosen-
sitivity toward MTX. Our study with clinical samples of childhood
ALL could not confirm the influence of the MTHFR 677CT
polymorphism on ex vivo MTX sensitivity, although a trend toward
decreased sensitivity was observed. Some of the discrepancies
might be explained by the different conditions used for the in vitro
assays. In our assay, high folate is present in the culture medium,
possibly counteracting changed folate redistribution due to polymor-
phisms in folate genes. The clinical results are possibly explained
by changed folate distribution. We have no explanation why only
the heterozygous MTHFR 1298AC variant showed decreased MTX
sensitivity whereas the homozygous (CC) variant did not.
Also, in other diseases in which MTX is being used, genetic
polymorphisms play a role. MTHFR 1298AC and not MTHFR
677CT modulated the efficacy of MTX treatment in rheumatoid
arthritis patients, whereas MTHFR 677CT was related to toxic-
ity.3,5 Both TS 2R/3R7,21 and RFC 80GA21 polymorphisms
influenced efficacy and not toxicity of low-dose MTX therapy in
patients with rheumatoid arthritis, whereas both MTHFR polymor-
phisms showed no effect.7
Our study is the first to report on the MTRR 66AG and
SHMT1 1420CT polymorphisms as pharmacogenetic determi-
nants of MTX treatment efficacy. Further studies are warranted to
evaluate the effect of these polymorphisms on enzyme activity and
on intracellular folate redistribution. However, increased risk of
neural tube defect pregnancy outcome and cardiovascular disease
have been associated with the MTRR 66AG polymorphism.22
SHMT1 1420CC individuals show increased homocysteine concen-
trations and lower folate status22 and exhibit an increased ALL
risk.17 TS competes with SHMT and MTHFR for methylenetetrahy-
drofolate.23 MTHFR 677CT and MTHFR 1298AC reduce in
vitro enzyme activity.14,15 MTHFR 677CT directs methylenetetra-
hydrofolate toward purine and pyrimidine synthesis at the expense
of methyltetrahydrofolate, and increases catalytic activity of TS.9,11
SHMT mediates the competition between TS and MTHFR for
one-carbon units: increased SHMT expression favors DNA synthe-
sis and inhibits homocysteine remethylation and S-adenosylmethi-
onine (SAM) synthesis.24 MTRR maintains adequate levels of
methyl-cobalamin, the activated cofactor of MS, and thus main-
tains MS in its active state. Low MTRR activity prevents MTR-
mediated remethylation of homocysteine and, because the MTHFR
reaction is irreversible, results in trapping of methyl-tetrahydrofo-
late with concomitant inhibition of purine and thymidylate biosyn-
thesis.23 We have no explanation why SHMT1 TT patients only
showed increased MTX resistance in the TSI50, cont.
In contrast to the TSI50, short, borderline significances were
observed for the TSI50, cont in our study. This may be due to the
lower number of patients in which the TSI50, cont was measured
(n  86) compared with the TSI50, short (n  120) with concomitant
lower statistical power. More likely, however, accumulation of
long-chain MTX polyglutamates is higher after continuous incuba-
tions (TSI50, cont), resulting in an increased inhibition capacity of
TS. As a consequence, TSI50, cont is less sensitive to changes in
folate redistribution due to polymorphisms in other folate-related
enzymes. The TSI correlates with conventional cytotoxic assays in
leukemic cell lines and the TSI50, short gives a better reflection of
clinical MTX sensitivity than the TSI50, cont.12
In conclusion, we show that the common polymorphisms in the
folate-related genes MTHFR, MTRR, and SHMT1 are related to in
vitro MTX sensitivity in pediatric patients with ALL. To date, the
MTX dose applied is based mostly on the body surface area, while
the patient’s cellular folate status or pharmacogenetic background25
is not yet routinely taken into account. Identifying predictors of
MTX sensitivity may lead to the development of individualized
treatment strategies with improved efficacy and reduced toxicity. In
some countries, but not The Netherlands, the TPMT polymorphism
is used to dose adjust the initial dose of 6-mercaptopurine. We feel
that in a similar way polymorphisms in folate-related genes such as
MTRR could be used to adjust the initial (not maintenance) MTX
dose once it is firmly established that these polymorphisms
influence efficacy and/or toxicity. In 500 healthy white subjects, we
established high allele frequencies of MTRR 66AG (55%),
MTHFR 1298AC (31%), and SHMT1 1420CT (32%). Athough
ethnic and geographic variations exist in these polymorphisms,
high allele frequencies have also been reported in other ethnic
groups and thus, they may significantly contribute to sensitivity and
toxicity associated with MTX treatment.
Table 2. Multivariate analysis of the effect of polymorphisms in
folate-related genes on in vitro MTX sensitivity (TSI50) of
childhood ALL
Polymorphism
Multivariate analysis
TSI50,cont, Stand  TSI50,short, Stand 
MTHFR 677C > T
CT vs CC 0.033 0.043
TT vs CC 0.044 0.067
MTHFR 1298A > C
AC vs AA 0.264* 0.281†
CC vs AA 0.064 0.074
MTR 2756 A > G
AG vs AA 0.100 0.047
GG vs AA 0.005 0.019
MTRR 66A > G
AG vs AA 0.272§ 0.399
GG vs AA 0.204 0.272‡
MTHFD1 1958G > A
GA vs GG 0.012 0.137
AA vs GG 0.060 0.003
SHMT1 1420 C > T
CT vs CC 0.002 0.026
TT vs CC 0.259‡ 0.096
TS 2R3R
3R2R vs 3R3R 0.088 0.058
2R2R vs 3R3R 0.034 0.012
RFC 80G > A
GA vs GG 0.043 0.003
AA vs GG 0.009 0.057
The standardized regression coefficient of each independent variable is given as
standardized  (Stand ) in multivariate analysis. Because independent variables
may have different units, the strength of the regression coefficients () may not be
comparable and therefore the coefficients are standardized to their means (Stand )
for comparison reasons. In univariate regression, the strength of the association
between each independent variable and the dependent variable (outcome measure)
is looked at without taking into account the other independent variables; in contrast, in
multiple linear regression, the strength of each independent variable is adjusted by
the other independent variables in the model. No significant interactions were
observed in multiple regression analysis for MTHFR 677CT*MTHFR 1298AC,
MS2756 AG*MTRR 66AG, MTHFR 677CT*MTHFD1 1958GA, and MTHFR
677CT*MTHFD1 1958GA.
*P 006.
†P .01.
‡P .05.
§P .08.
P .001.
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